RECHERCHE :   Cancers de la peau
Filtrage ? Le champ de filtrage permet de trier les études comportant le mot saisie. La recherche du mot se fait uniquement dans le contenu texte affiché à l'écran.
ETUDE PHASE SITE
A2A-005: A randomized, double-blind, placebo-controlled, Phase 2 study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with nonsquamous non-small cell lung cancer who have progressed on immunotherapy
carcinome pulmonaire non à petites cellules non épidermoïde
II
CHUV
AGENUS_C-800-23: A multicohort, open label, phase 2 study of botensilimab (AGEN1181) for treatment of advanced melanoma refractory to prior Checkpoint Inhibitor therapy
Stage III (unresectable) or Stage IV cutaneous melanoma
II
CHUV
BERING: Encorafenib plus binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutated melanoma: a multicentric, national, prospective, longitudinal, non-interventional study in Switzerland
Melanoma
autre
CHUV
CA027-002: A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers
Tumeurs solides avancés (plusieurs cohortes avec des indications spécifiées)
I, II
CHUV
CA224-127: A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma
Mélanome
III
CHUV
0024-CHUV-DO-LANCE-2020
Localized Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
II
CHUV
IMPulse-2020: A phase I, first in human, dose finding study of high dose rate radiotherapy in patients with skin metastases from melanoma
Mélanome métastatique
I
CHUV
INCA 33890-101: A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Part 1a: Histologically or cytologically confirmed advanced or metastatic solid tumors as follows: BC (pure small-cell carcinoma, pure adenocarcinoma, and pure squamous cell carcinoma are exlucded) - CESC - ESCA - GC - GEJ - Mel - MPM - NSCLC (mixed small-cell and non-small cell lung cancer histology is exlcluded - tumors should not exhibit mutations in EFGR, ALK, ROS1, BRAF) - OC (Sertoli-Leydic or germ cell cancers are excluded) - RCC - SCCHN (Carcinoma of the nasopharynx, salivary gland, or nonsquamous histologies are excluded) - TNBC - PAAD - CRC. Part1b: same as part 1a, plus dMMR/MSI-H CRC and MSS-CRC
I
CHUV
IT-IO: Intrathecal administration of anti-PD1/anti-CTLA-4 in combination with systemic combination of anti-PD1/anti- CTLA-4 in patients with NSCLC without oncogenic driver mutation or melanoma and newly diagnosed leptomeningeal metastasis: a multicentric phase I study
NSCLC without oncogenic driver mutation or melanoma and newly diagnosed leptomeningeal metastasis
I
HUG
KEYVIBE- 010: A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma
high-risk resected melanoma
III
CHUV, HUG
MK-3475-U02: A Phase 1/2 Open-label Rolling-arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma
Melanoma
I, II
HUG